Oppenheimer initiated coverage on Y-mAbs Therapeutics with a new price target

11/18/24 8:23:54 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Oppenheimer initiated coverage of Y-mAbs Therapeutics with a rating of Outperform and set a new price target of $23.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$YMAB

Date	Price Target	Rating	Analyst
4/22/2025	$3.00	Neutral → Underperform	BofA Securities
11/18/2024	$23.00	Outperform	Oppenheimer
8/16/2024	$20.00	Overweight	Cantor Fitzgerald
6/28/2024	$21.00	Buy	Truist
5/10/2023	$5.00 → $13.00	Neutral → Outperform	Wedbush
4/3/2023		Buy → Neutral	Guggenheim
1/27/2023	$4.00	Equal-Weight → Underweight	Morgan Stanley
1/5/2023		Outperform → Market Perform	Cowen